{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Percentage of participants with partial or complete response by Bladé criteria. Partial response is defined as a \\>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \\< 5% plasma cells.","groups":[{"description":"therapeutic autologous lymphocytes\n\ntherapeutic tumor infiltrating lymphocytes\n\nmelphalan\n\nautologous hematopoietic stem cell transplantation","id":"OG000","title":"MILs in Patients Undergoing an Autologous Peripheral SCT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Disease Response","type":"PRIMARY","unitOfMeasure":"Participants"}